Age (years) | 56.4 ± 12.9 | Laboratory data | |
---|---|---|---|
Male, n (%) | 10/11 (90.9) | Hemoglobin (g/dL) | 10.0 ± 1.5 |
Body mass index (kg/m2) | 25.3 ± 2.6 | Serum albumin (g/dL) | 3.1 ± 0.4 |
PD treatment period (year) | 3.4 ± 1.3 | Serum blood urea nitrogen (mg/dL) | 58.0 ± 22.5 |
Etiology of renal insufficiency | Diabetes mellitus (7) | Serum creatinine (mg/dL) | 15.1 ± 4.6 |
Glomerulonephritis (2) | Serum sodium (mEq/L) | 134.1 ± 2.6 | |
Polycystic kidney disease (1) | Serum potassium (mEq/L) | 4.0 ± 0.5 | |
Renal sclerosis (1) | Serum calcium (mg/dL) | 4.0 ± 0.6 | |
Urine volume (mL/day) | 100 (0–1050) | Serum phosphorus (mg/dL) | 6.7 ± 2.3 |
Renal Kt/V urea | 0.01 ± 0.01 | Intact parathyroid hormone (pg/mL) | 239.2 ± 99.5 |
Renal CCr (mL/min) | 4.7 ± 5.5 | C-reactive protein (mg/dL) | 0.8 ± 1.5 |
Peritoneal dialysis treatment | Serum beta 2 microglobulin (mg/L) | 32.7(30.7–51.2) | |
Total PD fluid volume (L/day) | 9.5 ± 2.2 | ||
Weekly Kt/V | 1.6 ± 0.3 |
Hemodialysis treatment conditions | ||||
---|---|---|---|---|
HD sessions per week | 1 | Dialyzer type (n) | Ia | 10 |
Treatment time per HD session (hours) | 4 | IIa | 1 | |
Blood flow rate (mL/min) | 200 (200–250) | Membrane area of the dialyzers (m2) | 2.4 ± 0.2 |